OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Alfonso Piérola on Unmet Needs in Higher-Risk MDS

April 25th 2023

Ana Alfonso Piérola, MD, PhD, discusses unmet needs for patients with high-risk myelodysplastic syndrome.

Dr Llanos on Prediagnositic Allostatic Load and Breast Cancer Clinicopathology in Black Women

April 25th 2023

Adana A.M. Llanos, PhD, MPH, discusses the relationship between prediagnostic allostatic load and breast cancer clinicopathology in Black women.

Dr Venugopal on Challenges With the Diagnosis of BPDCN

April 25th 2023

Sangeetha Venugopal, MD, MS, discusses the importance of increasing awareness of blastic plasmacytoid dendritic cell neoplasm to improve early diagnosis and treatment for patients with BPDCN at academic centers.

Dr Nakshatri on the Investigation of TONSL in Breast Cancers

April 25th 2023

Harikrishna Nakshatri, BVSc, PhD, discusses the investigation of TONSL in patients with breast cancer.

Dr Herbst on the Implications of the AEGEAN Trial in NSCLC

April 24th 2023

Roy S. Herbst, MD, PhD, discusses the implications of the phase 3 AEGEAN trial in patients with resectable non–small cell lung cancer.

Dr Garon on Challenges Associated With Immunotherapy Use in EGFR-mutated NSCLC

April 24th 2023

Edward B. Garon, MD, MS, discusses challenges associated with the incorporation of immunotherapy into the treatment paradigm for EGFR-mutant non–small cell lung cancer.

Dr Sullivan on Pseudoprogression as a Potential Explanation for Outcomes With Tebentafusp in Uveal Melanoma

April 24th 2023

Ryan J. Sullivan, MD, explains the prolongation of survival with tebentafusp-tebn despite apparent initial radiographic tumor progression in patients with uveal melanoma.

Dr Sullivan on ctDNA Reduction After Tebentafusp Treatment in Uveal Melanoma

April 24th 2023

Ryan J. Sullivan, MD, discusses findings from a study investigating the effects of early circulating tumor DNA reduction on overall survival in patients with uveal melanoma treated with tebentafusp.

Dr Marconi on the Investigation of Tamibarotene Plus Azacitidine in Higher-risk MDS

April 21st 2023

Giovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.

Dr Hamilton on the Potential of RLY-2608 in PI3K-Mutated Breast Cancer

April 21st 2023

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research, Sarah Cannon Research Institute, discusses the potential of the PI3K inhibitor RLY-2608 in PI3K-mutated breast cancer.

Dr Kaseb on the Investigation of Adjuvant Atezolizumab and Bevacizumab in Early-Stage HCC

April 21st 2023

Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.

Dr Reckamp on the Effect of Adjuvant Atezolizumab on Patient Outcomes in Resectable Stage IB-IIIA NSCLC

April 21st 2023

Karen L. Reckamp, MD, MS, discusses updated findings from the phase 2 LCMC3 trial in resectable stage IB to IIIB non–small cell lung cancer.

Women in Oncology: Self-Advocacy in a Busy Field

April 20th 2023

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.

Women in Oncology: Career Challenges Turned Growth Opportunities

April 20th 2023

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss challenges they faced throughout their early careers and how some of those challenges continue to affect the professional lives of female physicians.

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors

April 20th 2023

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

Dr Ademuyiwa on the Sequencing of First-line CDK4/6 Inhibitors in HR+/HER2– Breast Cancer

April 20th 2023

Foluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.

Dr Rodriguez on TKIs in Lung Cancers With Uncommon EGFR Mutations

April 19th 2023

Estelamari Rodriguez, MD, MPH, discusses the benefits of the TKIs afatinib and osimertinib in patients with lung cancer with uncommon EGFR mutations.

Dr Mekhail on Afatinib in Lung Cancers With Uncommon EGFR Mutations

April 19th 2023

Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd, discusses the prevalence of uncommon EGFR mutations in patients with lung cancer, research needs for these patients, and how the findings from the phase 3 LUX-Lung 3 and LUX-Lung 6 trials support the use of afatinib in this population.

Dr Andreeff on the Rationale for Investigating Uproleselan Plus Venetoclax and Azacitidine in AML

April 19th 2023

Michael Andreeff, MD, PhD, discusses the rationale for investigating uproleselan plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Dr Ball on Prior Research Supporting the SELECT-AML-1 Trial in Newly Diagnosed AML

April 19th 2023

Brian C. Ball, MD, discusses previous research on tamibarotene in newly diagnosed acute myeloid leukemia, and how these data support the ongoing phase 2 SELECT-AML-1 trial.